A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT01087151 · COMPLETED
Trial details
- NCT number
- NCT01087151
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-08-01
- Primary completion
- 2012-06-01
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.